Proposed Data Collections Submitted for Public Comment and Recommendations, 8737-8738 [E7-3333]

Agencies

• Centers for Disease Control and Prevention
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 72, Number 38 (Tuesday, February 27, 2007)]
[Notices]
[Pages 8737-8738]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-3333]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-07-05CZ]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call 404-639-5960 
and send comments to Joan Karr, CDC Acting Reports Clearance Officer, 
1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to 
omb@cdc.gov.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Written comments should be received 
within 60 days of this notice.

Proposed Project

    Assessing Diabetes Detection Initiative for Policy Decision--New--
National Center for Chronic Disease Prevention and Health Promotion 
(NCCDPHP), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    Type 2 diabetes is a chronic disease that affects more than 18 
million Americans, approximately 5 million of whom do not know that 
they have the disease. As the disease progresses, it often causes 
severe complications, including heart disease, blindness, lower 
extremity arterial disease, and kidney failure. American Indians, 
African Americans, Latino Americans, and some Asian Americans and 
Pacific Islanders are disproportionately affected by diabetes. 
Identifying persons who have undiagnosed diabetes and treating them 
could prevent or delay diabetes complications.
    In November 2003 the Diabetes Detection Initiative (DDI) was 
launched in 10 locations around the U.S. to identify a portion of the 
estimated 5 million people with undiagnosed Type 2 diabetes, targeting 
specific areas in each of 10 locales in which residents are likely to 
be at higher risk for Type 2 diabetes. Implementation of the DDI 
involved distributing a paper-and-pencil risk test. Individuals whose 
score indicated that they were at an increased risk for diabetes were 
advised to see their regular doctor (or to schedule an appointment at 
one of several clinics that had agreed to participate in the DDI), to 
receive a finger-stick or other tests to confirm whether or not they 
have diabetes. Whether or not the DDI should be expanded to other 
communities depends on the health benefits and costs of the program. 
The CDC is planning to conduct a study to provide this critical 
information.
    The planned study will assess the resources used, the cost per case 
detected, and the perceived benefit of the DDI to participants. Data 
for the economic assessment will be obtained by conducting three 
separate surveys: (1) A local implementation team survey will be 
administered to the 10 DDI local implementation leaders to obtain 
information on resources used by the members of DDI local 
implementation teams and community based organizations to implement the 
non-medical service delivery activities for the DDI program; (2) a 
health clinic

[[Page 8738]]

leadership survey will be sent to the clinic directors in each of the 
43 clinics that participated in the DDI across the 10 locations to 
obtain information on the cost of delivering the medical services 
required in diabetes screening and diagnosis; and (3) a patient survey 
will be administered to a sample of 600 patients at the 43 
participating clinics to obtain information regarding patient out-of-
pocket medical and non-medical direct health care costs and the 
perceived economic benefits of diabetes screening. The results of the 
study will also provide information needed for conducting a more 
complete cost-effectiveness analysis of screening for undiagnosed 
diabetes.
    The local implementation team survey will be mailed to the local 
DDI implementation team leader in each of the 10 regions to collect 
information regarding the staff time and other resources used to 
implement the DDI program (including the staff time and resources used 
by community-based organizations that participated in the DDI 
implementation). These planning and implementation activities include 
participating in meetings and conference calls, recruiting clinics and 
community-based organizations to participate in the DDI, distributing 
risk tests, organizing health fairs and other community events, and 
designing media campaigns to promote the DDI.
    The health clinic leadership survey will be mailed to the clinic 
director at each of the 43 clinics across the 10 locations that 
participated in the DDI implementation. The survey will collect 
information regarding the costs associated with the clinic's 
participation in the DDI. These will include the medical costs of 
providing care to patients who visited the clinic as a result of the 
DDI, staff time associated with DDI planning and implementation, and 
any staff time that was devoted to performing finger stick tests at 
locations other than the health clinic (e.g., health fairs, shopping 
malls, work sites, housing complexes). Of the 43 clinics to be 
surveyed, we expect that 30 (70%) will complete the survey.
    A computer-assisted in-person patient survey will be administered 
to a sample of 600 clinic patients at the 43 clinics that participated 
in the DDI. The survey will collect background information, out-of-
pocket medical and non-medical direct health care costs (e.g., co-
payments, transportation costs, value of patients' time associated with 
the clinic visit), and preferred features of a diabetes screening 
program. There are no costs to respondents other than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                         Average
                                                         No. of          No. of        burden per       Total
                    Respondents                        respondents    responses per   response  (in  burden  (in
                                                                       respondent        hours)         hours)
----------------------------------------------------------------------------------------------------------------
Implementation team members........................              10               1               2           20
Clinic staff.......................................              30               1               1           30
Patients at DDI clinics............................             600               1           20/60          200
����������������������������������������������������
    Total..........................................  ..............  ..............  ..............          250
----------------------------------------------------------------------------------------------------------------


    Dated: February 22, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and 
Prevention.
[FR Doc. E7-3333 Filed 2-26-07; 8:45 am]
BILLING CODE 4163-18-P